prev

CKR - Taking the High Road

The restaurant industry is facing significant challenges in 2008 and many in the QSR segment are addressing the issues by discounting. CKR chose not to discount and instead, raised prices 4%, which helped both blended same-store sales growth and average unit volumes.
  • In the most recent quarter, management reduced G&A expense slightly (down 10 bps YOY as a percent of sales), but there appears to be room for further cost cutting. And with Ramius LLC's recent letter raising concerns over CKR's high G&A expenses (relative to its competitors), management appears motivated to bring these costs down in the near-term, with CEO Andrew Puzder citing that keeping G&A under control is one of the two big strategic initiatives within the company (the other being managing commodity costs).
  • Looking out over the next few quarters, things should to improve for CKR as the company is lapping some easier revenue and margin comparisons in 2Q and in the back half of the year. CKR's refranchising efforts at Hardee's really picked up in 2H08 with the company refranchising 60 restaurants in 3Q and 30 in 4Q, which negatively impacted company-operated revenue growth. Although the company plans to refranchise additional units in FY09, there are only 40 units remaining under CRK's current refranchising schedule so the negative impact on revenues will be minimal relative to last year. Management continues to maintain that each refranchised restaurant reduces G&A spending by about $22-$24 thousand and that the costs are eliminated immediately when the stores are sold, but these savings have not yet helped to bring the company's overall G&A spending down to a more reasonable level.
  • From a margin standpoint, CKR should see some benefit in 2Q because it will be lapping the initial spike in food and packaging costs that it experience last year, particularly at Hardee's (up 130 bps YOY as a percent of sales on a consolidated basis and up 200 bps YOY at Hardee's in 2Q08). Increasing beef costs should offset some of this year-over-year favorability, however, as the company mentioned that it is already seeing beef prices rising in 2Q, which was not an issue in 1Q. The company's stance on discounting ( we will not deal with the issues by trying to drive business through discounting our products, serving inferior products or massively couponing ) should also help protect margins going forward as long as its ongoing price increases don't hurt traffic growth, like we saw at SONC and CBRL.

CSX: What Happened To The "Smart" Activists?

I've been harping about how ridiculous this CSX hedge fund story is and how it was conveniently marked at a May month end high of $69.06. I'm not saying that anyone in particular marked it there. I am saying it looks suspect. Today the stock closed -11.8% lower than that day of May 30th. What a difference a month makes...

"Me-Too" activist investing is a by-product of the leverage cycle. As cost of capital increases, and access to capital tightens, some of these concentrated "activist" funds will just go away.
KM

(chart courtesy of stockcharts.com)

Myriad (MYGN): The Day After, big +12.9% alpha move!

Our new head of Healthcare at Research Edge, Tom Tobin, issued the following note before the open yesterday to his exclusive network. Big alpha day for Tom. I'm psyched to be partnered with him again!

If you're interested in our Healthcare research, please email Tom at

Here's his MYGN note from the morning of 6/30/08:

MYGN!!
"The exclamation points are probably not necessary given the near universal dismissal of the compound. What's left is a fast growing, profitable, bankers dream of a diagnostics company.

I am sure there are pitch books on the desks of company management discussing the merits of splitting the Pharmaceutical and Molecular Diagnostics companies. I agree with the move. Management is killing the Flurizan development program after $68M in costs and they should probably kill drug development altogether and get on with the business of genetic testing.

Molecular Diagnostics revenue growth is running above 50% with EBITDA margins at 51%, and EBITDA of $29M for the March quarter. MYGN shares look like they will open around 42, or 12X EV/EBITDA on just the Molecular Diagnostics business. With the short interest at 30% of the float, I'd bet the shares are higher from here.

Tom Tobin
Managing Director
Healthcare

(Chart courtesy of stockcharts.com)

Daily Trading Ranges

20 Proprietary Risk Ranges

Daily Trading Ranges is designed to help you understand where you’re buying and selling within the risk range and help you make better sales at the top end of the range and purchases at the low end.

LEH +4.9% on the day... See, I Can Buy Things!

I fielded my fair share of questions as to how I could be so bearish as to think Lehman was going to $20, but received zero emails after I bought it there. Such is life in the fishbowl!

Oh, and by the way, there was no "take under" today.
KM

*Full Disclosure: I am long LEH

(chart courtesy of stockcharts.com)

Eye On Populism...

The State employees of Utah are moving to a 4 day work week, allegedly...

This just in from USA Today.com of all places: "Utah this summer will become what experts say is the first state to institute a mandatory four-day work week for most state employees, joining local governments across the nation that are altering schedules to save money, energy and resources"...

http://www.usatoday.com/news/nation/2008-06-30-four-day_N.htm?se=yahoorefer

KM

KKD - You can't make this stuff up!

The opportunity to take KKD private has come and gone. Daryl Brewster, the Ex CEO, had one shot and he did not get it done. At current prices, KKD is trading at 13x LTM TEV/EBITDA and the EBITDA is not growing, but declining. It's hard to find another restaurant company that is more expensive than KKD. So why would some unknown asset management firm try to buy the company at $7.50? This has to be a joke. If this bid is real, I wish I could short the company buying it.

The best part of the whole story is what is being reported by the Winston-Salem Journal. The article questions the legitimacy of Dee Guess, the managing director of MGL Asset Management. Apparently, Mr. Guess has had multiple lawsuits filed against him and has used known aliases including Mario Guess, J.D. Guess and Jerry D. Guess. The paper also said, "There is no listing of principals in the company, no companies under MGL's management or ownership, and no track record of the principals managing and owning businesses." MGL was listed as incorporating in January on the N.C. Secretary of State's Web site.

There is nothing better than a warm glazed Krispy Kreme doughnut. Unfortunately, stiff competition, razor thin margins and rising commodity costs put significant pressure on the business model. The international opportunity is real, but not enough to offset the pending pressure on the domestic business.

real-time alerts

real edge in real-time

This indispensable trading tool is based on a risk management signaling process Hedgeye CEO Keith McCullough developed during his years as a hedge fund manager and continues to refine. Nearly every trading day, you’ll receive Keith’s latest signals - buy, sell, short or cover.

next